Research ArticleOriginal Article
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
Ming Bai, Meng Wang, Ting Deng, Yuxian Bai, Kai Zang, Zhanhui Miao, Wenlin Gai, Liangzhi Xie and Yi Ba
Cancer Biology & Medicine March 2022, 19 (3) 358-369; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0388
Ming Bai
1Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
Meng Wang
1Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
Ting Deng
1Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
Yuxian Bai
2Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China
Kai Zang
3Department of Medical Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
Zhanhui Miao
4Oncology Department, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
Wenlin Gai
5Sinocelltech Ltd., Beijing 100176, China
Liangzhi Xie
5Sinocelltech Ltd., Beijing 100176, China
6Beijing Engineering Research Center of Protein and Antibody, Beijing 100176, China
7Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100176, China
Yi Ba
1Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
References
- 1.↵
- Bray F,
- Ferlay J,
- Soerjomataram I,
- Siegel RL,
- Torre LA,
- Jemal A.
- 2.↵
- 3.↵
- Arnold M,
- Soerjomataram I,
- Ferlay J,
- Forman D.
- 4.↵
- 5.↵
- Muro K,
- Lordick F,
- Tsushima T,
- Pentheroudakis G,
- Baba E,
- Lu Z, et al.
- 6.↵
- Shirakawa T,
- Kato K,
- Nagashima K,
- Nishikawa A,
- Sawada R,
- Takahashi N, et al.
- 7.↵
- 8.↵
- 9.↵
- 10.↵
- 11.↵
- Jia J,
- Cui Y,
- Lu M,
- Wang X,
- Li J,
- Li J, et al.
- 12.
- Jia W,
- Wang W,
- Ji C-S,
- Niu J-Y,
- Lv Y-J,
- Zhou H-C, et al.
- 13.↵
- Song J,
- Shi W,
- Zhang Y,
- Sun M,
- Liang X,
- Zheng S.
- 14.↵
- 15.
- Meng X,
- Wang J,
- Sun X,
- Wang L,
- Ye M,
- Feng P, et al.
- 16.
- 17.↵
- Liang J,
- E M,
- Wu G,
- Zhao L,
- Li X,
- Xiu X, et al.
- 18.↵
- Suntharalingam M,
- Winter K,
- Ilson D,
- Dicker AP,
- Kachnic L,
- Konski A, et al.
- 19.↵
- 20.↵
- Hu X,
- Jiang H,
- Bai W,
- Liu X,
- Miao Q,
- Wang L, et al.
- 21.↵
- Weiner LM,
- Belldegrun AS,
- Crawford J,
- Tolcher AW,
- Lockbaum P,
- Arends RH, et al.
- 22.↵
- Eisenhauer EA,
- Therasse P,
- Bogaerts J,
- Schwartz LH,
- Sargent D,
- Ford R, et al.
- 23.↵
- Huang J,
- Xu B,
- Liu Y,
- Huang J,
- Lu P,
- Ba Y, et al.
- 24.↵
- Kato K,
- Cho BC,
- Takahashi M,
- Okada M,
- Lin C-Y,
- Chin K, et al.
- 25.↵
- Crosby T,
- Hurt CN,
- Falk S,
- Gollins S,
- Mukherjee S,
- Staffurth J, et al.
- 26.↵
- Zhang X,
- Jia J,
- Lu M,
- Wang X,
- Gong J,
- Li J, et al.
- 27.↵
- 28.↵
- 29.↵
- Kang N,
- Wang Y,
- Guo S,
- Ou Y,
- Wang G,
- Chen J, et al.
- 30.↵
- Niyaz M,
- Ainiwaer J,
- Abudureheman A,
- Zhang L,
- Sheyhidin I,
- Turhong A, et al.
- 31.↵
- Wierzbicki R,
- Jonker DJ,
- Moore MJ,
- Berry SR,
- Loehrer PJ,
- Youssoufian H, et al.
- 32.↵
- Maubec E,
- Petrow P,
- Scheer-Senyarich I,
- Duvillard P,
- Lacroix L,
- Gelly J, et al.
- 33.↵
- Strumberg D,
- Schultheis B,
- Scheulen ME,
- Hilger RA,
- Krauss J,
- Marschner N, et al.
- 34.↵
- Rischin D,
- Spigel DR,
- Adkins D,
- Wein R,
- Arnold S,
- Singhal N, et al.
- 35.
- Siano M,
- Molinari F,
- Martin V,
- Mach N,
- Früh M,
- Freguia S, et al.
- 36.↵
- Terazawa T,
- Kato T,
- Goto M,
- Ohta K,
- Noura S,
- Satake H, et al.
In this issue
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
Ming Bai, Meng Wang, Ting Deng, Yuxian Bai, Kai Zang, Zhanhui Miao, Wenlin Gai, Liangzhi Xie, Yi Ba
Cancer Biology & Medicine Mar 2022, 19 (3) 358-369; DOI: 10.20892/j.issn.2095-3941.2021.0388
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
Ming Bai, Meng Wang, Ting Deng, Yuxian Bai, Kai Zang, Zhanhui Miao, Wenlin Gai, Liangzhi Xie, Yi Ba
Cancer Biology & Medicine Mar 2022, 19 (3) 358-369; DOI: 10.20892/j.issn.2095-3941.2021.0388
Jump to section
Related Articles
- No related articles found.